InVivoMAb anti-mouse 4-1BB (CD137)

Optimization of 4-1BB antibody for cancer immunotherapy by balancing agonistic strength with FcgammaR affinity. Qi X et al., 2019 May 20, Nat Commun

Unique potential of 4-1BB agonist antibody to promote durable regression of HPV+ tumors when combined with an E6/E7 peptide vaccine. Bartkowiak T et al., 2015 Sep 22, Proc Natl Acad Sci U S A

Curing mice with large tumors by locally delivering combinations of immunomodulatory antibodies. Dai M et al., 2015 Mar 1, Clin Cancer Res

Anaphylaxis caused by repetitive doses of a GITR agonist monoclonal antibody in mice. Murphy JT et al., 2014 Apr 3, Blood

Combinatorial PD-1 blockade and CD137 activation has therapeutic efficacy in murine cancer models and synergizes with cisplatin. Wei H et al., 2013, PLoS One

Combined TIM-3 blockade and CD137 activation affords the long-term protection in a murine model of ovarian cancer. Guo Z et al., 2013 Sep 17, J Transl Med

Long-lasting complete regression of established mouse tumors by counteracting Th2 inflammation. Dai M et al., 2013 May, J Immunother

CD4+ T cells develop antiretroviral cytotoxic activity in the absence of regulatory T cells and CD8+ T cells. Manzke N et al., 2013 Jun, J Virol

Localized immunotherapy via liposome-anchored Anti-CD137 + IL-2 prevents lethal toxicity and elicits local and systemic antitumor immunity. Kwong B et al., 2013 Mar 1, Cancer Res

Combination CTLA-4 blockade and 4-1BB activation enhances tumor rejection by increasing T-cell infiltration, proliferation, and cytokine production. Curran MA et al., 2011 Apr 29, PLoS One